Friedhofer Henri, Camargo Cristina Pires, Oshiro Leandro Hirokazu, Valente Daniel de Almeida Rocha, Gemperli Rolf
Division of Plastic Surgery, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.
Einstein (Sao Paulo). 2024 Nov 29;22:eRC1111. doi: 10.31744/einstein_journal/2024RC1111. eCollection 2024.
Agents that inhibit programmed cell death (IPD-1) in T lymphocytes are indicated for patients with advanced cancer. However, some individuals may develop endocrinological conditions, such as diabetes, thyroid dysfunction, and lipodystrophy, after treatment. This systematic review and case report of IPD-1 lipodystrophies describes a patient who received nivolumab treatment for advanced clear cell renal carcinoma and subsequently developed diabetes as well as facial and body lipodystrophy. The patient complained of social distress due to her facial appearance. We treated the facial lipodystrophy with autologous fat grafting, which proved to be effective for more than three years. This study showed the efficacy of IPD-1 lipodystrophy treatment with long-term follow-up.
抑制T淋巴细胞程序性细胞死亡（IPD-1）的药物适用于晚期癌症患者。然而，一些患者在治疗后可能会出现内分泌疾病，如糖尿病、甲状腺功能障碍和脂肪代谢障碍。这篇关于IPD-1脂肪代谢障碍的系统综述和病例报告描述了一名接受纳武单抗治疗晚期透明细胞肾细胞癌的患者，该患者随后出现了糖尿病以及面部和身体脂肪代谢障碍。患者因面部外观而抱怨社交困扰。我们采用自体脂肪移植治疗面部脂肪代谢障碍，该方法在三年多的时间里证明是有效的。这项研究显示了IPD-1脂肪代谢障碍治疗的长期随访疗效。
